A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.

Phase 1CompletedNCT00220818

Takeda24 enrolled

Overview

The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.

A Phase 1, multicenter, pharmacokinetic/Pharmacodynamic and safety study in which infants will be randomized in an open-label fashion to receive 5 days of open-label treatment with lansoprazole pediatric suspension 1 mg/kg/day oral, or lansoprazole pediatric suspension 2 mg/kg/day oral. On Dosing Days 1 and 5, blood samples will be obtained for drug assay. All subjects will be evaluated for inclusion in the pH monitoring portion of the study and will undergo pH monitoring, provided it is clinically indicated, at the discretion of the investigator. Intragastric pH monitoring (up to 24 hours) will be performed at Baseline, on Dosing Day 1 (or Day 2) and on Dosing Day 5 (or Day 6). Intraesophageal pH may be done in addition to intragastric pH at the discretion of the investigator. Subjects will be evaluated for safety, including a follow-up visit on Post-Dosing Day 14.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastroesophageal Reflux Disease

Interventions

LansoprazoleDRUG

Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.

LansoprazoleDRUG

Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.

Eligibility

Sex: ALLMin age: 29 DaysMax age: 364 Days

Medical Language ↔ Plain English

Inclusion Criteria: * Hospitalized or outpatient male or female, term or post-term infants beyond the neonatal period (\>28 days) but less than 12 months of age, OR a preterm infant with a corrected age of at least 44 weeks but less than 12 months on Dosing Day 1. * Clinically-evident Gastroesophageal Reflux Disease (feeding intolerance, regurgitation, wheezing or stridor with feedings) * At least 7 days post-surgery without anticipated need for surgery during study * No significant laboratory abnormalities Exclusion Criteria: * Unstable, clinically significant disease or abnormality * Congenital anomaly of the upper gastrointestinal tract * Clinical evidence of acute sepsis * Cystic fibrosis * Medical condition requiring subject to not be fed by mouth/gastric tube

Outcomes

Primary Outcomes

Pharmacokinetic Analysis.

Time frame: Day 1 and 5

Mean Intragastric 24 hour pH (subset of 6 subjects)

Time frame: Day -1, 1 and 5

Secondary Outcomes

Gastroesophageal Reflux Disease Symptom Assessment.

Time frame: Days 1-5

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.